Forodesine

Forodesine

Names
IUPAC name 7-[(2S,3S,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-2-pyrrolidinyl]-1,5-dihydropyrrolo[2,3-e]pyrimidin-4-one
Other names Immucillin H
Identifiers
CAS Number	209799-67-7
ChEMBL	ChEMBL218291
ChemSpider	392417
Jmol interactive 3D	Image
KEGG	D06596
PubChem	444499
UNII	426X066ELK
InChI InChI=1S/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1 Key: IWKXDMQDITUYRK-KUBHLMPHSA-N InChI=1/C11H14N4O4/c16-2-5-9(17)10(18)7(15-5)4-1-12-8-6(4)13-3-14-11(8)19/h1,3,5,7,9-10,12,15-18H,2H2,(H,13,14,19)/t5-,7+,9-,10+/m1/s1 Key: IWKXDMQDITUYRK-KUBHLMPHBW
SMILES C1=C(C2=C(N1)C(=O)NC=N2)[C@H]3[C@@H]([C@@H]([C@H](N3)CO)O)O
Properties
Chemical formula	C11H14N4O4
Molar mass	266.25 g/mol
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
verify (what is  ?)
Infobox references

Forodesine (INN; also known as Immucillin H) is a transition-state analog inhibitor of purine nucleoside phosphorylase^[1] under development for the treatment of relapsed B-cell chronic lymphocytic leukemia

Immucillin H was originally discovered by Vern Schramm's laboratory at the Albert Einstein College of Medicine in New York and Industrial Research Limited in New Zealand.

Forodesine is being developed by BioCryst Pharmaceuticals as Fodosine. As of 2008, it is currently in phase II clinical trials.^[2]

References

1. Kicska GA, Long L, Hörig H; et al. (April 2001). "Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes". Proc. Natl. Acad. Sci. U.S.A. 98 (8): 4593–8. doi:10.1073/pnas.071050798. PMC 31879. PMID 11287638.
2. "Complete list of clinical trials for forodesine (BCX-1777) (ClinicalTrials.gov)". Retrieved 2008-07-22.

External links

• "From cell biology to therapy: forodesine". Hematology Meeting Reports 2 (5): 106–111. 2008.